144 related articles for article (PubMed ID: 37690647)
1. Design and evaluation of α-helix-based peptide inhibitors for blocking PD-1/PD-L1 interaction.
Rui M; Zhang W; Mi K; Ni H; Ji W; Yu X; Qin J; Feng C
Int J Biol Macromol; 2023 Dec; 253(Pt 2):126811. PubMed ID: 37690647
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.
Orafaie A; Sadeghian H; Bahrami AR; Rafatpanah H; Matin MM
Bioorg Med Chem; 2021 Jan; 30():115951. PubMed ID: 33360579
[TBL] [Abstract][Full Text] [Related]
3. Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy.
Liu H; Zhao Z; Zhang L; Li Y; Jain A; Barve A; Jin W; Liu Y; Fetse J; Cheng K
J Immunother Cancer; 2019 Oct; 7(1):270. PubMed ID: 31640814
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of PD-1 derived peptides as inhibitors of PD-1/PD-L1 complex formation for cancer therapy.
Bojko M; Węgrzyn K; Sikorska E; Kocikowski M; Parys M; Battin C; Steinberger P; Kogut MM; Winnicki M; Sieradzan AK; Spodzieja M; Rodziewicz-Motowidło S
Bioorg Chem; 2022 Nov; 128():106047. PubMed ID: 35963023
[TBL] [Abstract][Full Text] [Related]
5. In silico screening and surface plasma resonance-based verification of programmed death 1-targeted peptides.
Zhang P; Li C; Ji X; Gao M; Lyu S; Dai X; Du J
Chem Biol Drug Des; 2020 Mar; 95(3):332-342. PubMed ID: 31755641
[TBL] [Abstract][Full Text] [Related]
6. Effect of the hairpin structure of peptide inhibitors on the blockade of PD-1/PD-L1 axis.
Wang K; Song Y; Su Y; Liang Y; Wang L
Biochem Biophys Res Commun; 2020 Jun; 527(2):453-457. PubMed ID: 32336542
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Cyclic Peptide Inhibitors Targeting PD-L1 for Cancer Immunotherapy.
Fetse J; Zhao Z; Liu H; Mamani UF; Mustafa B; Adhikary P; Ibrahim M; Liu Y; Patel P; Nakhjiri M; Alahmari M; Li G; Cheng K
J Med Chem; 2022 Sep; 65(18):12002-12013. PubMed ID: 36067356
[TBL] [Abstract][Full Text] [Related]
8. Rational design and development of a peptide inhibitor for the PD-1/PD-L1 interaction.
Boohaker RJ; Sambandam V; Segura I; Miller J; Suto M; Xu B
Cancer Lett; 2018 Oct; 434():11-21. PubMed ID: 29920293
[TBL] [Abstract][Full Text] [Related]
9. Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles.
Guzik K; Tomala M; Muszak D; Konieczny M; Hec A; Błaszkiewicz U; Pustuła M; Butera R; Dömling A; Holak TA
Molecules; 2019 May; 24(11):. PubMed ID: 31151293
[TBL] [Abstract][Full Text] [Related]
10. Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction.
Wang F; Ye W; He Y; Zhong H; Zhu Y; Han J; Gong X; Tian Y; Wang Y; Wang S; Ji S; Liu H; Yao X
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835382
[TBL] [Abstract][Full Text] [Related]
11. Discovery of benzo[d]isothiazole derivatives as novel scaffold inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction through "ring fusion" strategy.
Gao Y; Wang H; Shen L; Xu H; Deng M; Cheng M; Wang J
Bioorg Chem; 2022 Jun; 123():105769. PubMed ID: 35405572
[TBL] [Abstract][Full Text] [Related]
12. Structure-based derivation and intramolecular cyclization of peptide inhibitors from PD-1/PD-L1 complex interface as immune checkpoint blockade for breast cancer immunotherapy.
Zhou K; Lu J; Yin X; Xu H; Li L; Ma B
Biophys Chem; 2019 Oct; 253():106213. PubMed ID: 31276987
[TBL] [Abstract][Full Text] [Related]
13. Rational Design of Potent Peptide Inhibitors of the PD-1:PD-L1 Interaction for Cancer Immunotherapy.
Yin H; Zhou X; Huang YH; King GJ; Collins BM; Gao Y; Craik DJ; Wang CK
J Am Chem Soc; 2021 Nov; 143(44):18536-18547. PubMed ID: 34661406
[TBL] [Abstract][Full Text] [Related]
14. A PD-L1 and VEGFR2 dual targeted peptide and its combination with irradiation for cancer immunotherapy.
Jiao L; Dong Q; Zhai W; Zhao W; Shi P; Wu Y; Zhou X; Gao Y
Pharmacol Res; 2022 Aug; 182():106343. PubMed ID: 35798286
[TBL] [Abstract][Full Text] [Related]
15. Investigation of protein-protein interactions and hot spot region between PD-1 and PD-L1 by fragment molecular orbital method.
Lim H; Chun J; Jin X; Kim J; Yoon J; No KT
Sci Rep; 2019 Nov; 9(1):16727. PubMed ID: 31723178
[TBL] [Abstract][Full Text] [Related]
16. Kaempferol and Its Glycoside, Kaempferol 7-O-Rhamnoside, Inhibit PD-1/PD-L1 Interaction In Vitro.
Kim JH; Kim YS; Choi JG; Li W; Lee EJ; Park JW; Song J; Chung HS
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32375257
[TBL] [Abstract][Full Text] [Related]
17. Develop a PD-1-blockade peptide to reinvigorate T-cell activity and inhibit tumor progress.
Qin Y; Meng X; Li L; Liu C; Gao F; Yuan X; Huang Y; Zhu Y
Eur J Pharmacol; 2023 Dec; 960():176144. PubMed ID: 37866745
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, evaluation, and SAR of 4-phenylindoline derivatives, a novel class of small-molecule inhibitors of the programmed cell death-1/ programmed cell death-ligand 1 (PD-1/PD-L1) interaction.
Yang Y; Wang K; Chen H; Feng Z
Eur J Med Chem; 2021 Feb; 211():113001. PubMed ID: 33272783
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Programmed Death Receptor-1/Programmed Death Ligand-1 Interactions by Ginsenoside Metabolites.
Yim NH; Kim YS; Chung HS
Molecules; 2020 Apr; 25(9):. PubMed ID: 32365500
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy.
Shen W; Shi P; Dong Q; Zhou X; Chen C; Sui X; Tian W; Zhu X; Wang X; Jin S; Wu Y; Chen G; Qiu L; Zhai W; Gao Y
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]